Company / EPS (Diluted)
Janux Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.83
FY2025
5-year range
-$1.83 / -$1.28
FY2021-FY2025
Trend
-43.0%
vs FY2024
Sector context
#116 of 204
Health Care
What the data says
At $-1.83, Janux Therapeutics, Inc.'s eps (diluted) ranks #116 of 204 in the Health Care sector. Declined from $-1.32 to $-1.83 over the past 2 years.
Based on SEC 10-K filings.
-1.83 in FY2025.
Declined from $-1.32 to $-1.83 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#116 of 204 in Health CareTop 57% of 204This company -$1.83 Sector average -$1.03
▼
-77.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 43.0% year-over-year.
- Ranks #116 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.83 | -43.0% |
| FY2024 | -$1.28 | +3.0% |
| FY2023 | -$1.32 | +13.2% |
| FY2022 | -$1.52 | -9.4% |
| FY2021 | -$1.39 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026